These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 30579574)

  • 1. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
    Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N
    Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia.
    Fefeu M; De Maricourt P; Cachia A; Hoertel N; Vacheron MN; Wehbe E; Rieu C; Olie JP; Krebs MO; Gaillard R; Plaze M
    Psychiatry Res; 2018 Dec; 270():205-210. PubMed ID: 30267984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.
    Chartier F; Rouillon F; Berggren L; Jamonneau I; Falissard B; Llorca PM
    Encephale; 2017 Aug; 43(4):303-310. PubMed ID: 28709669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E; McCrone P
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
    Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
    BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.
    Barbosa WB; Costa JO; de Lemos LLP; Gomes RM; de Oliveira HN; Ruas CM; Acurcio FA; Barbui C; Bennie M; Godman B; Guerra AA
    Appl Health Econ Health Policy; 2018 Oct; 16(5):697-709. PubMed ID: 30051254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
    Samalin L; Garay R; Ameg A; Llorca PM
    Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
    Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL].
    Gasquet I; Flandre P; Heurtebize N; Deal C; Perrin E; Chartier F; Fourrier-Réglat A
    Encephale; 2009 Feb; 35(1):25-31. PubMed ID: 19250990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.